Your browser doesn't support javascript.
loading
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma.
Mori, Nami; Tamaki, Nobuharu; Takaki, Shintaro; Tsuji, Keiji; Tada, Toshifumi; Nakamura, Shinichiro; Ochi, Hironori; Mashiba, Toshie; Doisaki, Masao; Marusawa, Hiroyuki; Kobashi, Haruhiko; Fujii, Hideki; Ogawa, Chikara; Nonogi, Michiko; Arai, Hirotaka; Uchida, Yasushi; Urawa, Naohito; Narita, Ryoichi; Akahane, Takehiro; Kondo, Masahiko; Yasui, Yutaka; Tsuchiya, Kaoru; Izumi, Namiki; Kurosaki, Masayuki.
Afiliación
  • Mori N; Department of Gastroenterology, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
  • Tamaki N; Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo, 180-8610, Japan.
  • Takaki S; Department of Gastroenterology, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
  • Tsuji K; Department of Gastroenterology, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
  • Tada T; Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Japan.
  • Nakamura S; Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Japan.
  • Ochi H; Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Japan.
  • Mashiba T; Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Japan.
  • Doisaki M; Department of Gastroenterology and Hepatology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan.
  • Marusawa H; Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan.
  • Kobashi H; Department of Gastroenterology, Japanese Red Cross Okayama Hospital, Okayama, Japan.
  • Fujii H; Department of Gastroenterology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
  • Ogawa C; Department of Gastroenterology and Hepatology, Takamatsu Red Cross Hospital, Takamatsu, Japan.
  • Nonogi M; Department of Gastroenterology, Tokushima Red Cross Hospital, Tokushima, Japan.
  • Arai H; Department of Gastroenterology, Maebashi Red Cross Hospital, Maebashi, Japan.
  • Uchida Y; Department of Gastroenterology, Matsue Red Cross Hospital, Matsue, Japan.
  • Urawa N; Department of Gastroenterology and Hepatology, Ise Red Cross Hospital, Ise, Japan.
  • Narita R; Department of Gastroenterology, Oita Red Cross Hospital, Oita, Japan.
  • Akahane T; Department of Gastroenterology, Ishinomaki Red Cross Hospital, Ishinomaki, Japan.
  • Kondo M; Department of Gastroenterology, Otsu Red Cross Hospital, Otsu, Japan.
  • Yasui Y; Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo, 180-8610, Japan.
  • Tsuchiya K; Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo, 180-8610, Japan.
  • Izumi N; Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo, 180-8610, Japan.
  • Kurosaki M; Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo, 180-8610, Japan. kurosakim@gmail.com.
Invest New Drugs ; 2024 Aug 30.
Article en En | MEDLINE | ID: mdl-39212893
ABSTRACT
Although immune checkpoint inhibitors (ICI) are used for unresectable hepatocellular carcinoma (HCC), it is unclear whether sequential ICI treatment-durvalumab plus tremelimumab (DT) after progression on atezolizumab plus bevacizumab (AB)-is effective for HCC. In this nationwide multicenter study, we aimed to investigate the effect of DT treatment based on the timing of treatment. A total of 85 patients receiving DT treatment were enrolled. The primary endpoint is treatment response at week 8 among patients receiving first-line DT treatment, those receiving second-line or later treatment without prior AB therapy, and those receiving second-line or later treatment with prior AB therapy. Objective response rates (ORRs) in patients with first-line treatment, second-line treatment without AB, and second-line treatment with prior AB were 44%, 54%, and 5%, respectively (p < 0.001). Similarly, disease control rates (DCRs) were 69%, 91%, and 26%, respectively (p < 0.001). ORR and DCR were significantly lower in patients with prior AB treatment. Progression free survival (PFS) was significantly shortened in patients receiving second-line therapy following prior AB treatment and an adjusted hazard ratio (95% confidence interval) in those patients for PFS, using first-line therapy as a reference, was 2.35 (1.1-5.1, p = 0.03). In conclusion, the impact of DT sequencing following AB treatment was limited. However, even after second-line treatment, the treatment effect can be equivalent to that of first-line treatment in cases with no history of AB treatment. Thus, prior treatment history should be taken into account when initiating DT treatment.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Invest New Drugs Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Invest New Drugs Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos